Brokerage Firm Rating Update on EnteroMedics (ETRM)

EnteroMedics (ETRM) : 1 brokerage houses believe that EnteroMedics (ETRM) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on EnteroMedics (ETRM). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 2 Wall Street Analysts endorse the stock as a Buy with a rating of 2.


Company shares have received an average consensus rating of Hold for the current week Also, In the latest statement by the brokerage house, Roth Capital downgrades its outlook on EnteroMedics (NASDAQ:ETRM). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Buy. The brokerage firm lowers the price target from $3 per share to $0.5 per share. The rating by the firm was issued on June 9, 2016.

EnteroMedics (NASDAQ:ETRM): The stock opened at $0.14 and touched an intraday high of $0.154 on Wednesday. During the day, the stock corrected to an intraday low of $0.137, however, the bulls stepped in and pushed the price higher to close in the green at $0.1423 with a gain of 4.25% for the day. The total traded volume for the day was 6,127,384. The stock had closed at $0.1365 in the previous trading session.

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Companys neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Companys initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.